Limitations, agreements, and source contact

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas · Source last updated 2021-11-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

wyndham_wilson@nih.gov

organization

National Cancer Institute

phone

240-760-6092

title

Dr. Wyndham Wilson

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice